VIDEO: Ongoing trial on use of radiotherapy with ipilimumab, nivolumab in metastatic RCC
Click Here to Manage Email Alerts
Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.
The study was presented at the 2022 ASCO Genitourinary Cancers Symposium.
“This study is really exploring whether the combination of giving radiation plus immune checkpoint blockade can make a difference in patients with metastatic kidney cancer,” Ball, who is the associate program director of the Urologic Oncology Fellowship and assistant research physician in the Urologic Oncology Branch of the National Cancer Institute, told Healio.
“The rationale here is one that has been discussed for years, and that’s really can radiotherapy prime the immune system to release antigens that are then recognized by the immune system, and we can really ramp that up with immune checkpoint blockade,” he added, noting that the trial is still ongoing and that he is “really interested to see if there is some benefit” to this approach.
Collapse
Healio Interview
Lalani AKA, et al. Poster Presentation 10. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 17-19, 2022; San Francisco.
Read more about
Click Here to Manage Email Alerts